Explore emgality®, the first and only cgrp antibody approved for both the preventive treatment of migraine and the treatment of episodic cluster headache in adults. Samples inquiry may only be requested by prescribing healthcare professionals. Emgality was discontinued in many of the reported cases
Includes emgality approval status, regulatory history and clinical trial results. Please complete the form below and submit to eli lilly and company to inquire about samples and/or a sales representative Request an emgality® loading dose kit sample for preventative treatment of migraine by filling out a form.
Pharmacology, adverse reactions, warnings, and emgalityside effects. Emgalitytm (galcanezumab) emgality, also known as galcanezumab, is a prescription medication by eli lilly for the preventive treatment of migraine in adults Emgality was fda approved september 2018 This page is designed to answer some of the frequently asked questions about emgality, as well as provide some helpful resources
Learn about side effects, cost, dosage, and more of emgality (galcanezumab), a prescription injection used to prevent migraine and treat cluster headaches. Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with emgality in clinical studies and the postmarketing setting. Licensed healthcare professionals can request complimentary product samples for patients directly from novo nordisk in three easy steps The sample /sales representative inquiry form is a resource for healthcare professionals
